Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10


Anacetrapib as a potential cardioprotective strategy.

Di Bartolo BA, Nicholls SJ.

Drug Des Devel Ther. 2017 Dec 7;11:3497-3502. doi: 10.2147/DDDT.S114104. eCollection 2017. Review.


Therapeutic modulation of the natural history of coronary atherosclerosis: lessons learned from serial imaging studies.

Andrews J, Puri R, Kataoka Y, Nicholls SJ, Psaltis PJ.

Cardiovasc Diagn Ther. 2016 Aug;6(4):282-303. doi: 10.21037/cdt.2015.10.02. Review.


Interrogating causal pathways linking genetic variants, small molecule metabolites, and circulating lipids.

Shin SY, Petersen AK, Wahl S, Zhai G, Römisch-Margl W, Small KS, Döring A, Kato BS, Peters A, Grundberg E, Prehn C, Wang-Sattler R, Wichmann HE, de Angelis MH, Illig T, Adamski J, Deloukas P, Spector TD, Suhre K, Gieger C, Soranzo N.

Genome Med. 2014 Mar 28;6(3):25. doi: 10.1186/gm542. eCollection 2014.


Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis.

Li C, Zhang W, Zhou F, Chen C, Zhou L, Li Y, Liu L, Pei F, Luo H, Hu Z, Cai J, Zeng C.

PLoS One. 2013 Oct 28;8(10):e77049. doi: 10.1371/journal.pone.0077049. eCollection 2013. Review.


Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.

Mohammadpour AH, Akhlaghi F.

Clin Pharmacokinet. 2013 Aug;52(8):615-26. doi: 10.1007/s40262-013-0071-8.


Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.

Miyares MA, Davis K.

Vasc Health Risk Manag. 2012;8:483-93. doi: 10.2147/VHRM.S29010. Epub 2012 Aug 23. Review.


Familial hypercholesterolemia: present and future management.

Sjouke B, Kusters DM, Kastelein JJ, Hovingh GK.

Curr Cardiol Rep. 2011 Dec;13(6):527-36. doi: 10.1007/s11886-011-0219-9. Review.


Diversity through phosphine catalysis identifies octahydro-1,6-naphthyridin-4-ones as activators of endothelium-driven immunity.

Cruz D, Wang Z, Kibbie J, Modlin R, Kwon O.

Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):6769-74. doi: 10.1073/pnas.1015254108. Epub 2011 Mar 7.


Novel HDL-directed pharmacotherapeutic strategies.

Degoma EM, Rader DJ.

Nat Rev Cardiol. 2011 May;8(5):266-77. doi: 10.1038/nrcardio.2010.200. Epub 2011 Jan 18. Review.


The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?

Vergeer M, Holleboom AG, Kastelein JJ, Kuivenhoven JA.

J Lipid Res. 2010 Aug;51(8):2058-73. doi: 10.1194/jlr.R001610. Epub 2010 Apr 6. Review.

Supplemental Content

Support Center